Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -44,539 | -21,668 | -24,579 | -122,545 | -7,291 |
| Depreciation Amortization | 6,897 | 1,426 | 497 | 459 | 98 |
| Accounts receivable | -12 | 527 | -262 | -659 | N/A |
| Other Working Capital | -1,801 | -1,941 | 3,710 | -2,291 | -999 |
| Other Operating Activity | 23,619 | 1,248 | -342 | 101,548 | 91 |
| Operating Cash Flow | $-15,836 | $-20,408 | $-20,976 | $-23,488 | $-8,101 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -365 | -19 | -47 | -154 | -39 |
| Net Acquisitions | N/A | N/A | N/A | -22,707 | N/A |
| Other Investing Activity | 0 | 0 | 0 | 119 | 0 |
| Investing Cash Flow | $-365 | $-19 | $-47 | $-22,742 | $-39 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 5,292 | 18,003 | N/A | N/A | 310 |
| Debt Repayment | N/A | -1,500 | -2 | -942 | N/A |
| Common Stock Issued | 1,137 | 320 | 19,713 | 62,535 | 4,359 |
| Dividend Paid | N/A | -16 | -16 | -8 | N/A |
| Other Financing Activity | -169 | -251 | -116 | 0 | 0 |
| Financing Cash Flow | $6,260 | $16,556 | $19,579 | $61,585 | $4,669 |
| Beginning Cash Position | 11,670 | 15,541 | 16,985 | 1,630 | 5,101 |
| End Cash Position | 1,729 | 11,670 | 15,541 | 16,985 | 1,630 |
| Net Cash Flow | $-9,941 | $-3,871 | $-1,444 | $15,355 | $-3,471 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,836 | -20,408 | -20,976 | -23,488 | -8,101 |
| Capital Expenditure | -369 | -19 | -297 | -154 | -39 |
| Free Cash Flow | -16,205 | -20,427 | -21,273 | -23,642 | -8,140 |